Haplotypes of [-794(CATT) <subscript>5-8</subscript> /-173G>C] MIF gene polymorphisms and its soluble levels in cutaneous squamous cell carcinoma in western Mexican population.

Guevara-Gutiérrez, E ; Ramos-Súarez, M ; et al.

In: Molecular genetics & genomic medicine, Jg. 11 (2023-11-01), Heft 11, S. e2252

Online academicJournal

Zugriff:

Full Text Finder (Volltext)

Background: Some cytokines are strongly implicated in the development of squamous cell carcinoma (SCC) such as the Macrophage migration inhibitory factor (MIF). The haplotype -794 (CATT) 5-8 /-173G>C in MIF gene polymorphisms has been associated with some types of cancer. The aim of this study is to establish the possible association between the presence of this haplotype in the MIF gene and its subsequent soluble levels with the susceptibility of SCC in western Mexican population.

Methods: This study included 175 SCC patients and 175 age-sex-matched individuals as a reference group (RG) from western Mexico. Genomic DNA was extracted from peripheral blood leukocytes. Polymorphisms were genotyped by endpoint PCR and PCR-RFLP, and the determination of MIF serum levels was measured by ELISA. Clinical characteristics were evaluated by a group of dermatologists.

Results: Analysis of [-794(CATT) 5-8 /-173G>C] MIF gene polymorphisms showed that the 5C (OR = 2.7, p = 0.02) and the 7G (OR = 3.39, p < 0.01) haplotypes are associated with susceptibility in SCC. MIF soluble levels in SCC patients showed a median of 13.93 ng/mL, whereas the reference group showed 6.000 ng/mL.

Conclusions: Our findings suggest that 5C and 7G [-794(CATT) 5-8 /-173G>C] MIF gene haplotypes are associated with susceptibility to SCC and that SCC patients present increased soluble levels of MIF.

Titel:	Haplotypes of [-794(CATT) <subscript>5-8</subscript> /-173G>C] MIF gene polymorphisms and its soluble levels in cutaneous squamous cell carcinoma in western Mexican population.
Autor/in / Beteiligte Person:	Guevara-Gutiérrez, E ; Ramos-Súarez, M ; Villalobos-Ayala, RA ; Tlacuilo-Parra, A ; Muñoz-Valle, JF ; Tarango-Martínez, V ; Valle, Y ; Padilla-Gutiérrez, JR ; Rojas-Díaz, JM ; Valdés-Alvarado, E
Link:	Full Text Finder (Volltext)
Zeitschrift:	Molecular genetics & genomic medicine, Jg. 11 (2023-11-01), Heft 11, S. e2252
Veröffentlichung:	[Hoboken, NJ] : John Wiley & Sons, [2013]-, 2023
Medientyp:	academicJournal
ISSN:	2324-9269 (electronic)
DOI:	10.1002/mgg3.2252
Schlagwort:	Humans Haplotypes Mexico Genetic Predisposition to Disease Polymorphism, Genetic Intramolecular Oxidoreductases genetics Carcinoma, Squamous Cell genetics Skin Neoplasms genetics Macrophage Migration-Inhibitory Factors genetics
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Mol Genet Genomic Med] 2023 Nov; Vol. 11 (11), pp. e2252. <i>Date of Electronic Publication: </i>2023 Jul 24. MeSH Terms: Carcinoma, Squamous Cell* / genetics ; Skin Neoplasms* / genetics ; Macrophage Migration-Inhibitory Factors* / genetics ; Humans ; Haplotypes ; Mexico ; Genetic Predisposition to Disease ; Polymorphism, Genetic ; Intramolecular Oxidoreductases / genetics References: Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211038417. (PMID: 34416845) ; FASEB J. 2017 Feb;31(2):526-543. (PMID: 27825106) ; Int J Cancer. 2011 Nov 15;129(10):2463-72. (PMID: 21213214) ; J Dent Sci. 2021 Jan;16(1):342-348. (PMID: 33384818) ; Nucleic Acids Res. 1988 Feb 11;16(3):1215. (PMID: 3344216) ; FASEB J. 2009 Mar;23(3):720-30. (PMID: 18952710) ; Cytokine. 2013 Mar;61(3):759-65. (PMID: 23402792) ; Mol Genet Genomic Med. 2023 Nov;11(11):e2252. (PMID: 37485818) ; J Immunol Res. 2014;2014:704854. (PMID: 25105152) ; Urol J. 2019 Feb 21;16(1):32-36. (PMID: 30120767) ; Oncology. 2008;75(3-4):127-33. (PMID: 18791328) ; J Clin Lab Anal. 2020 May;34(5):e23209. (PMID: 31978276) ; Clin Exp Med. 2019 Aug;19(3):385-391. (PMID: 31102004) ; Biomedicines. 2018 Jan 02;6(1):. (PMID: 29301290) ; Mol Med Rep. 2016 May;13(5):3828-34. (PMID: 26985869) ; Tumour Biol. 2020 Jun;42(6):1010428320924524. (PMID: 32515296) ; Gac Med Mex. 2006 Nov-Dec;142(6):451-5. (PMID: 17201107) ; Circ Res. 2003 Aug 22;93(4):321-9. (PMID: 12881477) ; Rev Med Inst Mex Seguro Soc. 2011 May-Jun;49(3):253-8. (PMID: 21838992) ; J Surg Oncol. 2009 Aug 1;100(2):106-10. (PMID: 19475570) ; Thorac Cancer. 2019 Dec;10(12):2209-2217. (PMID: 31602798) ; BMC Res Notes. 2011 Oct 11;4:395. (PMID: 22168770) ; Pharmacol Ther. 2022 May;233:108024. (PMID: 34673115) ; Mol Carcinog. 2019 Oct;58(10):1809-1821. (PMID: 31219646) ; J Surg Res. 2010 May 1;160(1):29-34. (PMID: 19726058) ; Arthritis Rheum. 2002 Sep;46(9):2402-9. (PMID: 12355488) ; Mol Biol Evol. 1995 Sep;12(5):921-7. (PMID: 7476138) ; J Neuroimmunol. 2018 Jul 15;320:117-124. (PMID: 29661540) ; Nat Rev Rheumatol. 2019 Jul;15(7):427-437. (PMID: 31197253) ; Cytokine Growth Factor Rev. 2015 Aug;26(4):451-61. (PMID: 25882738) ; Br J Dermatol. 2017 Aug;177(2):373-381. (PMID: 28211039) ; PLoS One. 2018 Jun 4;13(6):e0197702. (PMID: 29864117) ; Br J Dermatol. 2012 May;166(5):1069-80. (PMID: 22251204) ; Drug Discov Today. 2013 Jun;18(11-12):592-600. (PMID: 23466524) ; J Investig Med. 2021 Jan;69(1):41-46. (PMID: 33046523) ; Hematol Oncol Clin North Am. 2019 Feb;33(1):1-12. (PMID: 30497667) ; Transl Cancer Res. 2019 Apr;8(2):647-654. (PMID: 35116797) ; Am J Med Genet C Semin Med Genet. 2004 Nov 15;131C(1):82-92. (PMID: 15468170) ; Photochem Photobiol. 2012 Sep-Oct;88(5):1157-64. (PMID: 22324658) Grant Information: PRODEP 2019 Universidad de Guadalajara Contributed Indexing: Keywords: carcinoma, squamous cell; cytokines; haplotypes; macrophage migration inhibition factors; polymorphism, genetic Substance Nomenclature: 0 (Macrophage Migration-Inhibitory Factors) ; EC 5.3.2.1 (MIF protein, human) ; EC 5.3.- (Intramolecular Oxidoreductases) Entry Date(s): Date Created: 20230724 Date Completed: 20231127 Latest Revision: 20231127 Update Code: 20231215 PubMed Central ID: PMC10655503

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.